Based on news intelligence, world brokerage firm CLSA stipulated that steel prices will not remain under pressure and there is no risk to earnings. JSW Steel has posted Rs 1745 million of profit in last quarter and hence it is worth to buy this stock with the target prices of Rs 395.
Sun Pharma and China Medical System Holdings engage into a License Agreement for Tildrakizumab in Greater China. This deal gives Sun Pharma grants to Greater China market for Tildrakizumab. China to become a valuable market in future as currently 5 million suffering from psoriasis and psoriatic arthritis . Tildrakizumab enjoys patents in China